Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary ...

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

Biogen has arrived at a highly unusual solution to a dispute surrounding a patent for its blockbuster multiple sclerosis drug Tecfidera. It has agreed to pay Denmark’s Forward Pharma $1.25 ...

Biogen finished a phase 1 trial of the drug candidate, BIIB113, in 2023. Work on another tau-focused treatment of early Alzheimer’s, the phase 2 antisense oligonucleotide BIIB080, is continuing.

The stock's fall snapped a seven-day winning streak.

Biogen shares have lost more than 40% of their ... Thai lawsuit targets Charoen Pokphand Foods over invasive fish impact 1:42 PM UTC · Updated ago Autos & Transportationcategory AutoZone misses ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Here’s what to look for. Biogen beat analysts’ revenue expectations by 1.2% last quarter, reporting revenues of $2.47 billion, down 2.5% year on year. It was a satisfactory quarter for the ...

Its MS segment is the largest but also has been losing momentum as 2024 revenues slipped 9% YoY to $1.07 billion. In Q4 2024, Biogen reported $3.44 per share earnings, which beat consensus analyst ...